In an article published in Law360, partner Rajat Rana, associate 𝗠𝗮𝗻𝘂𝗲𝗹 𝗩𝗮𝗹𝗱𝗲𝗿𝗿𝗮𝗺𝗮, and summer associate Madeleine Kim explore how investment treaties can help pharmaceutical and other foreign companies protect their intellectual property rights in China. https://lnkd.in/ecAqiaB3
Selendy Gay PLLC’s Post
More Relevant Posts
-
#ThisDayThatYear On April 11, 2001, the symbolic bell rang and Dr. Reddy's became the first pharmaceutical company in Asia, outside Japan, to be listed on the New York Stock Exchange (NYSE). In the words of our founder Dr. Anji Reddy, it "gave us credibility as a company with solid governance, and visibility with customers and employees." The listing provided us with access to the world's capital markets, gave us greater international visibility, and raised the bar of compliance to global regulatory standards. Here's a video #FromTheArchives that captures the moment! #GoodHealthCantWait #WeAreDrReddys
To view or add a comment, sign in
-
An overview for in-license deals in China in 2023 😀 In 2023, a total of over 170 in-licensing deals were completed in China, 2/3 of which, were transited from Chinese companies, others were followed by U.S companies, and companies from Japan, the U.K., Switzerland and other countries. Most of the deals were for the licensing rights for innovative medicines and technologies. Compared to previous years, the number of license in deals declined in 2023, but the total amount was essentially unchanged from 2022, mainly due to big deals ran by companies such as Beigene and Huadong Pharmaceuticals.
To view or add a comment, sign in
-
Since last Thursday (August 1), rumors have been rampant, and finally, they have been confirmed. As everyone guessed, it is the state-owned China Resources Group that is acquiring the private traditional Chinese medicine giant Tasly Pharmaceutical (hereinafter referred to as Tasly). On the afternoon of August 4, Tasly announced that Tasly Group would transfer 28% of its shares to China Resources Sanjiu and 5% to Guoxin Investment, making China Resources the new controlling shareholder of Tasly. Industry analysts suggest that the inclusion of Guoxin Investment is mainly to ensure that China Resources Sanjiu's shareholding does not exceed 30%, thus avoiding the trigger of a full takeover bid, which would complicate the acquisition process. Thus, while the company Tasly still exists, its identity as a private enterprise has exited the historical stage. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical
To view or add a comment, sign in
-
Partner @ Bird & Bird | China Intellectual Property - FLC (D.C. and NY) - Qualified (England & Wales, Hong Kong)
A new era for pharmaceutical cases in China: we start to see winning patent linkage cases enforcing the rights of international companies such as AstraZeneca v Sichuan Gowell, Chugai Pharma v Ouyi. In infringement cases: Boehringer Ingelheim v Sunshine Lake and a few more. Administrative enforcement action is the popular route nowadays. The statistic below is by no mean complete because China Judgment Online only contains some but far from all of the effective judgments. But it is definitely a change of scene from the half-Bolar ice age pre-2021.
To view or add a comment, sign in
-
The content discusses the issue of traditional knowledge (TK) misappropriation and exploitation by multinational corporations, particularly in the pharmaceutical industry. It highlights the clash between TK and modern legal systems, emphasizing the need for benefit sharing between indigenous communities and patent holders. The article provides examples from different regions, showcasing both successful benefit-sharing models and instances where TK was exploited without compensation. It also explores the interplay between TK and the patent process, emphasizing the need for a fair and equitable system that respects indigenous knowledge and supports mutual betterment.
To view or add a comment, sign in
-
The trade mark landscape is continuously evolving and pharmaceutical trade marks are no exception. Emily Sullivan explores the interesting pharmaceutical trade mark decisions issued by the EU General Court in 2023 – https://hubs.la/Q02fYVp10 Court of Justice of the European Union #Pharma #TradeMarks #IP #IntellectualProperty #MewburnTradeMarks #MewburnPharma #MewburnPharmaTM
Pharma trade marks: 2023 EU case law round up
mewburn.com
To view or add a comment, sign in
-
In the latest issue of The Monitor, the editors report on the favorable resolution Pomerantz achieved on behalf of 22 Israeli institutional investors in a group of opt-out suits against Teva Pharmaceutical Industries Ltd., one of the world’s largest manufacturers of generic drugs. The case concerned an alleged price-fixing scheme that has been called “likely the largest cartel in the history of the United States,” as well as Teva’s role in the devastating U.S. opioid crisis. In a major victory for global investors, during the litigation Pomerantz convinced the court to apply supplemental jurisdiction over claims under Israeli securities law, broadening the path for international investors to pursue recovery for securities fraud. Read more: https://lnkd.in/e9Y9K7mH #SecuritiesLaw #pharma #OpioidCrisis #SecuritiesLitigation
To view or add a comment, sign in
-
Novo Nordisk has long dominated the GLP-1 receptor market, but as generic competitors challenge their patents, the stakes are higher than ever. In his recent article for Law360, Pedram Sameni—Patexia’s CEO and an expert in the intellectual property landscape—delves into Novo Nordisk’s legal defense strategies, focusing on ANDA litigation, patent challenges, and the risks in this multibillion-dollar battle. 💡 Key Takeaways: ◾ With 37 patents protecting blockbuster drugs like Ozempic and Wegovy, Novo Nordisk is under mounting legal pressure as the Type 2 diabetes and obesity treatment market expands. ◾ Competitors like Viatris and Sun Pharma are using ANDA litigation and IPR filings to challenge patent validity, which could reshape the market landscape. ◾ A loss could mean billions in revenue, with up to 70-80% of market share slipping to generics within the first year of their entry. 📖 To uncover the legal strategies behind one of the most significant pharmaceutical battles of today, read the full article. #PatentLaw #ANDA #IPR #Pharmaceuticals #NovoNordisk #LegalInsights #IPTrends #PatentLitigation
To view or add a comment, sign in
-
Navigating the legal landscape of #lifesciences in #China? Our latest article explores the critical Chinese legal considerations for Out-Licensing and In-Licensing transactions in the pharmaceutical sector. Understand how Chinese companies can effectively license out their #IP and how non-Chinese companies can secure valuable technologies. Equip yourself with the knowledge to drive successful licensing and collaboration deals in this fast-growing market.
Top legal issues to think about in China-related licensing transactions
To view or add a comment, sign in
-
China Development Forum (CDF) and the China International Import Expo are two annual events where Big Pharma companies could collectively show their love for China. Last year, most CEOs from MNCs attended CDF online. This year, they've been busy meeting with government officials in parallel to the CDF conference. Commitments and compliments were made, but it remains to be seen what investments they will actually bring. And IP protection and further reform of the drug reimbursement system are two common concerns shared among the Big Pharma CEOs. #Pfizer #AstraZeneca #BristolMyersSquibb #Takeda #Novartis #GSK #Organon #Bayer #pharmaCEO #China #ChinaDevelopmentForum #CDF
Big Pharma CEOs gather in Beijing to show continued interest in China, offer policy advice
fiercepharma.com
To view or add a comment, sign in
3,099 followers